All participants – Page 5 – Communicable Diseases Research

Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents

이전 SARS-CoV-2 감염, 연령 및 노쇠는 요양원 거주자의 6개월 백신 유도 항스파이크 항체 역가와 관련이 있습니다

Article

Published on 2022-03-012022-09-11
Journal: Journal of the American Medical Directors Associat [Category] MERS, SARS, 진단, 치료법,

Patients receiving hemodialysis do not lose SARS-CoV-2 antibodies more rapidly than non-renal controls: a prospective cohort study

혈액 투석을받는 환자

Report

Published on 2022-02-282022-09-01
Journal: Renal failure [Category] COVID19(2023년), SARS, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adults All participants ANOVA antibody both groups Cellular immune response cellular immunity comparable Control coronavirus coronavirus disease COVID-19 COVID-19 diagnosis declined disease onset evaluated General population greater HD group Hemodialysis humoral IgG IgG level IgG levels immune responses increased risk individual Infection Kidney disease Kidney function magnitude maintain Maintenance hemodialysis Mortality participant Patient patients treated prospective cohort study quantified receiving remained respiratory Result SARS-CoV-2 SARS-CoV-2 antibody seropositive Seropositivity severe acute respiratory syndrome Coronavirus significantly lower Specific T-cell response study period subgroup of patients T-cell Response T-cell responses
[DOI] 10.1080/0886022X.2022.2042310 PMC 바로가기 [Article Type] Report

Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)

SARS-COV-2에 대한 예방 접종 전 항체 반응의 결정 인자 : 인구 기반 종단 연구 (Covidence UK)

Research Article

Published on 2022-02-222022-09-01
Journal: BMC Medicine [Category] COVID19(2023년), Fulltext, MERS, SARS, 진단,

[키워드] 95% CI adjusted adjusted odds ratio adjusted odds ratios alcohol alcohol consumption All participants anti-spike antibodies antibody Antibody Response Antibody titre antibody titres association behavioural BMI body mass body mass index COVID-19 disease COVID-19 disease severity determinant diet dried blood spot Dried blood spots enrolment Ethnicity exercise explained Factor geometric mean geometric mean ratio geometric mean ratios greater groups higher risk IgM responses independent independent of International investigated lifestyle LIGHT Linear regression Logistic lower risk micronutrients obese obesity Occupation online questionnaires participant Participants pharmacological physical Physical exercise positive swab pre-vaccination Prospective recruited response Result risk risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike glycoprotein serology seropositive seropositive participants Seropositivity Sociodemographic South Asian spike glycoprotein supplementary material test result titre Travel was obtained white
[DOI] 10.1186/s12916-022-02286-4 PMC 바로가기 [Article Type] Research Article

Is Being Physically Active Enough or Do People with Parkinson’s Disease Need Structured Supervised Exercise? Lessons Learned from COVID-19

신체 활동이 충분합니까 아니면 파킨슨병 환자에게 구조화된 감독 운동이 필요합니까? COVID-19에서 배운 교훈

Article

Published on 2022-02-192022-09-12
Journal: International Journal of Environmental Research an [Category] COVID19(2023년), MERS, SARS, 진단,

SARS-CoV-2 Seroprevalence in Healthcare Workers before the Vaccination in Poland: Evolution from the First to the Second Pandemic Outbreak

폴란드에서 예방 접종 전 의료 종사자의 SARS-CoV-2 혈청 유병률: 첫 번째 전염병 발생에서 두 번째 유행성 발병으로의 진화

Article

Published on 2022-02-172022-09-12
Journal: International Journal of Environmental Research an [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] 95%CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 All participants anti-SARS-CoV-2 association caused center community transmission coronavirus coronavirus disease COVID-19 demonstrated determine ELISA exhibited Factor HCW HCWs healthcare worker Healthcare workers hospital IgA IgG IgG/IgA seroprevalence immune response infections investigated Medicine Nurse Nurses occupational occupational medicine outbreak pandemic participant Participants questionnaire Regional reported Risk factors SARS-CoV-2 SARS-CoV-2 seroprevalence second second wave Serological assay serological assays Seropositivity Seroprevalence severe acute respiratory syndrome Coronavirus Severity of infection significant increase were used women worker
[DOI] 10.3390/ijerph19042319 PMC 바로가기 [Article Type] Article

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Covid-19 (회복)로 병원에 입원 한 환자의 Casirivimab 및 Imdevimab : 무작위, 통제, 오픈 라벨, 플랫폼 시험

Randomized Controlled Trial

Published on 2022-02-122022-08-13
Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료제,

[키워드] (Medical Research Council 1:1 28-day mortality 95% CI Administered Adverse reaction Adverse reactions All participants all randomly assigned patients all-cause mortality Analysis antibody assigned baseline baseline antibody status bleeding Cardiac arrhythmia Casirivimab cause-specific mortality clinically suspected Combination death detectable died dose Efficacy Efficacy and safety eligible Eligible participants enrolled evaluate finding funding hospital host cells humoral immune response Imdevimab Innovation Intention intention to treat intravenous infusion investigator investigators ISRCTN laboratory-confirmed SARS-CoV-2 infection Local major bleeding events Medical Research Council monoclonal antibody monoclonal antibody combination Mortality mounted non-competing monoclonal antibodies non-competing monoclonal antibody Open-label outcome p value participant Patient Platform trial Primary outcome randomisation randomised randomised, controlled, open-label platform trial Randomly randomly assigned patient rate ratio Receptor binding domain recovery reduced Registered reported Safety SARS-COV-2 infection SARS-CoV-2 spike glycoprotein SARS-CoV-2 vaccine Serious adverse reactions seronegative seronegative patient seronegative patients seropositive seropositive and seronegative patients Seven significantly single intravenous infusion spike glycoprotein Standard of care the SARS-CoV-2 thrombosis Treatment Trial UK hospital usual care usual care alone Viral viral entry with COVID-19
[DOI] 10.1016/S0140-6736(22)00163-5 PMC 바로가기 [Article Type] Randomized Controlled Trial

Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals

HIV에 감염된 개인에서 SARS-CoV-2 백신 접종 후 HIV-1 RNA 수준 및 항체 반응에 대한 영향

Immunology

Published on 2022-02-102022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법,

[키워드] a minor acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse effect All participant All participants Anti-RBD antibodies Anti-RBD antibody Anti-S1 antibody baseline baseline CD4 binding domain BNT162b2 CD4 T-cell collected coronavirus detectable dose elicited first dose HIV HIV-1 Immunological response Impact individual individuals Level male median median age minor mRNA vaccine mRNA vaccines mRNA1273 no statistical difference observational study offered Patient patients PLWH positive RBD reported respiratory response RNA SARS-CoV-2 second dose serology severe acute respiratory syndrome Coronavirus single-center T-cells vaccination Virological were measured with HIV
[DOI] 10.3389/fimmu.2021.820126 PMC 바로가기 [Article Type] Immunology

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

입원하지 않은 환자의 코로나19 경구 치료용 몰누피라비르

Clinical Trial

Published on 2022-02-102022-09-11
Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, 치료제,

[키워드] 95% CI 95% confidence interval active against acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse adverse event adverse events All participants Analysis Antiviral assigned baseline baseline characteristics conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 illness death demonstrated diabetes died double-blind early treatment Efficacy and safety efficacy end point end point Enrollment evaluate event Evidence evidence of Hospitalization Hospitalized Imbalance in some incidence interim analysis laboratory-confirmed Mild-to-moderate molnupiravir New oral participant Patient Phase 3 Placebo placebo group placebo-controlled trial progression randomization Randomized Randomly receive reduce reduced reported Result risk risk factor SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe COVID-19 illness Sex Sharp Subgroup analyses subgroups Symptom the placebo group Treatment Trial two groups Viral load was performed
[DOI] 10.1056/NEJMoa2116044 PMC 바로가기 [Article Type] Clinical Trial

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

브라질에서 코로나 박 코비드 -19 백신의 이전 수용자 (RHH-001)의 이전 수용자에서 이종과 동종 코비드 -19 부스터 백신 접종

Clinical Trial

Published on 2022-02-052022-08-13
Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술,

[키워드] 95% CI Ad26 Ad26.COV2-S Ad26.COV2-S vaccine Administered administration adverse events age All participant All participants anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody anti-spike IgG response Anti-spike IgG responses Antibody concentrations assigned AstraZeneca AZD1222 B.1.1.529 B.1.617.2 baseline binding blind BNT162b2 boost booster booster dose booster vaccination Booster vaccine Brazil ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Concentration CoronaVac COVID-19 COVID-19 vaccine detectable discharged home dose eligible ENhance except for finding FIVE for inclusion four groups funding geometric geometric mean geometric mean ratio geometric mean ratios group Heterologous homologous homologous booster responses IgG antibody IgG responses immune response immune responses immunogenicity IMPROVE inactivated Infection inferiority janssen Live virus neutralising antibodies Local local and systemic reactogenicity profiles Ministry of Health mRNA vaccine Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres non-inferiority non-inferiority margin Older Older adults Omicron variant Omicron variants outcome participant Pfizer Pfizer–BioNTech phase 4 primary analysis Primary outcome profiles pseudovirus neutralising antibodies randomisation randomised Randomly reached recipient recombinant adenoviral vectored vaccine recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine regimen Registered RHH-001 robust secondary Secondary outcomes Serious Adverse Events Seropositivity significant increase Sinovac stratified systemic reactogenicity the vaccine Vaccine vectored vaccine virus neutralising antibody whole-virion SARS-CoV-2 vaccine
[DOI] 10.1016/S0140-6736(22)00094-0 PMC 바로가기 [Article Type] Clinical Trial

Serologic Survey of IgG Against SARS-CoV-2 Among Hospital Visitors Without a History of SARS-CoV-2 Infection in Tokyo, 2020–2021

도쿄에서 SARS-CoV-2 감염 이력이 없는 병원 방문자 중 SARS-CoV-2에 대한 IgG의 혈청학적 조사, 2020-2021

Original Article

Published on 2022-02-052022-09-12
Journal: Journal of Epidemiology [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] 95% CI 95% confidence interval Against age All participants anti–SARS-CoV-2 IgG antibody blood collection Capital chemiluminescence immunoassay China confirmed cases coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19-related symptom COVID-19-related symptoms cross-sectional cross-sectional study diagnosed ENhance Epidemic exhibited high risk history hospital hospital visitors iFlash IgG IgG seroprevalence individual Infection Japan participant Patient positive result Randomly Respiratory Coronavirus Result SARS-CoV-2 SARS-CoV-2 epidemic SARS-COV-2 infection selected serologic seropositive Seroprevalence serum serum sample serum samples Sex Shenzhen Shenzhen YHLO Biotech survey the SARS-CoV-2 Tokyo Visitor was tested
[DOI] 10.2188/jea.JE20210324 PMC 바로가기 [Article Type] Original Article